Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H11N5O5S |
Molecular Weight | 289.268 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=NC=C1[N+]([O-])=O)N2CCN(C2=O)S(C)(=O)=O
InChI
InChIKey=FNSHYEAUAUHIMB-UHFFFAOYSA-N
InChI=1S/C8H11N5O5S/c1-10-6(13(15)16)5-9-7(10)11-3-4-12(8(11)14)19(2,17)18/h5H,3-4H2,1-2H3
Satranidazole is a drug that helps to combat a large number of varied health disorders effectively. This drug participated in clinical trials in patients of amebic liver abscess, where it showed a far lower incidence of side effects and had a significantly better tolerance than metronidazole. Besides, satranidazole has been studied an adjunct to scaling and root planning in the treatment of chronic periodontitis. satranidazole has a low polar surface area, high dose, and dosing frequency. Nanosizing with appropriate stabilizers and programmed processing conditions successfully produced SAT-NC with improved pharmaceutic and pharmacokinetic characteristics.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Randomized, single-blind, placebo-controlled multicenter trial to compare the efficacy and safety of metronidazole and satranidazole in patients with amebic liver abscess. | 2006 Dec |
|
Determination and evaluation of solubility parameter of satranidazole using dioxane-water system. | 2010 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17103040
Twenty-five patients received metronidazole (800 mg TID) and 24 received satranidazole (300 mg TID with placebo at mealtime).
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C277
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
41841
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
PRIMARY | |||
|
4N7G8A6439
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
PRIMARY | |||
|
DTXSID60204840
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
PRIMARY | |||
|
C034473
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105542
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
PRIMARY | |||
|
5199
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
PRIMARY | |||
|
C72155
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
PRIMARY | |||
|
100000084100
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
PRIMARY | |||
|
56302-13-7
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
PRIMARY | |||
|
SUB10459MIG
Created by
admin on Fri Dec 15 16:05:05 GMT 2023 , Edited by admin on Fri Dec 15 16:05:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY